CASE REPORT article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1591489
This article is part of the Research TopicBiomarker Discovery and Therapeutic Innovations in Genito-Urinary Cancer ManagementView all 17 articles
Combination Therapy with Toripalimab and Lenvatinib in Metastatic Type 2 Papillary Renal Cell Carcinoma: A Case Report
Provisionally accepted
- The Department of Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Type 2 papillary renal cell carcinoma (PRCC) is an aggressive subtype of renal cell carcinoma with a poor prognosis. Diagnosis is challenging, particularly when presenting as a metastatic lung mass. This report describes a case of metastatic type 2 PRCC treated with first-line toripalimab (anti-PD-1) and lenvatinib (multikinase inhibitor), highlighting sustained clinical benefit. Case presentation: A 73-year-old man presented with cough, hemoptysis, and a large left lung mass initially misdiagnosed as primary lung cancer. Multidisciplinary re-evaluation, including immunohistochemistry (PAX8+, P504s+, also known as AMACR), confirmed metastatic type 2 PRCC. After 11 months of toripalimab (flat dose of 240 mg every 3 weeks) and lenvatinib (flat dose of 8 mg daily), serial imaging demonstrated partial response (PR) with regression of pulmonary metastases, lymphadenopathy, and obstructive pneumonia. No serious adverse events occurred. Conclusions: This case underscores the potential efficacy and tolerability of toripalimab-lenvatinib combination therapy in metastatic type 2 PRCC. Further clinical trials are warranted to validate this approach.
Keywords: type 2 papillary renal cell carcinoma, Immunotherapy, Toripalimab, Lenvatinib, p504s
Received: 11 Mar 2025; Accepted: 21 Oct 2025.
Copyright: © 2025 Wang, Chen, Xue and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: De Zeng, dezeng@stu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.